Johnson & Johnson drops OSE’s rheumatoid arthritis drug

Johnson & Johnson drops OSE’s rheumatoid arthritis drug

Submitted by admin on November 2, 2018 - 7:56pm
Source: 
Fierce Biotech
News Tags: 
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
Headline: 
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
snippet: 
Johnson & Johnson has dumped OSE Immunotherapeutics’ autoimmune candidate FR104. J&J picked up the rights to the CD28 antagonist for €10 million ($11 million) upfront in 2016, but clinical progress stalled following the deal. 

Do Not Allow Advertisers to Use My Personal information